[1]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17-20.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(01):17-20.[doi:10.20148/j.fmj.2024.01.005]
点击复制

EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年01期
页码:
17-20
栏目:
临床研究
出版日期:
2024-02-15

文章信息/Info

Title:
Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients
文章编号:
1002-2600（2024）01-0017-04
作者:
钟颖; 邹立; 陈声池
福建医科大学附属南平第一医院，南平 353000
Author(s):
ZHONG Ying; ZOU Li;  CHEN Shengchi
Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian 353000, China
关键词:
非小细胞肺癌; 阿美替尼; 突变丰度; 疗效
Keywords:
non-small cell lung cancer;  Almonertinib;  mutation abundance;  efficacy
分类号:
R734.2
DOI:
10.20148/j.fmj.2024.01.005
文献标志码:
B
摘要:
目的分析阿美替尼治疗晚期非小细胞肺癌疗效，并探索EGFR T790M突变丰度与阿美替尼疗效之间的关系。方法回顾性分析52例接受阿美替尼治疗的经一/二代EGFR-TKIs耐药的Ⅲ期或Ⅳ期EGFR T790M突变的非小细胞肺癌患者，采用Kaplan-Meier法及Cox模型进行预后分析，并通过ROC曲线分析确定疗效相关的T790M突变丰度临界值。结果入组肺癌患者接受阿美替尼治疗的ORR为48.1%，DCR为94.2%。外周血T790M丰度中位值为1.94%。阿美替尼治疗患者的丰度最佳临界值为2.05%，将突变丰度≥2.05%的患者纳入高丰度组（25例），＜2.05%的患者纳入低丰度组（27例），高丰度值和低丰度值的ORR分别为84.0%和14.8%，PFS分别为12.8个月和7.2个月，OS分别为22.2个月和18.3个月。Cox回归分析显示，基因类型、性别、吸烟史、是否脑转移均不是阿美替尼治疗患者PFS的影响因素，外周血EGFR T790M突变丰度是PFS的独立影响因素。结论EGFR T790M突变丰度可能可预测阿美替尼治疗的晚期EGFR T790M 突变NSCLC患者的有效率和生存期。
Abstract:
ObjectiveTo analyze the efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer, and to explore the relationship between the abundance of EGFR T790M mutation and the efficacy of Almonertinib. MethodsA retrospective analysis of 52 patients with stage Ⅲ and stage-Ⅳ non-small cell lung cancer accompanied with EGFR T790M mutation who were treated with Almonertinib and were resistant to EGFR TKI in the first/second generation was carried out. The Kaplan-Meier method and Cox model were used to analyze the prognosis, and the critical value of T790M mutation abundance related to the efficacy was explored. ResultsThe ORR and DCR of the patients with lung cancer who received the treatment of Almonertinib were 48.1% and 94.2% respectively. The median abundance of T790M in peripheral blood was 1.94%.The cutoff value of abundance in patients treated with Almonertinib was 2.05%. Patients with mutation abundance≥2.05% were included in the high abundance group(25 cases), and patients with mutation abundance<2.05% were included in the low abundance group(27 cases). The ORR of the high abundance group and the low abundance group was 84.0% and 14.8% respectively, and the PFS was 12.8 months and 7.2 months respectively, and the OS was 22.2 months and 18.3 months respectively. Cox regression analysis showed that gene type, sex, smoking history, and brain metastasis were not factors influencing PFS in patients treated with Almonertinib, and the EGFR T790M mutation abundance in peripheral blood was an independent influencing factor of PFS. ConclusionThe abundance of EGFR T790M mutation may predict the effective rate and survival of patients with NSCLC with advanced EGFR T790M mutation treated with Almonertinib.

参考文献/References:

[1] GAO S,LI N,WANG S,et al.Lung Cancer in People's Republic of China [J].Journal of Thoracic Oncology,2020,15(10):1567-1576.
[2] Hatami E,Nagesh P K B,Jaggi M,et al. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer[J].European Journal of Pharmacology,2020,888:173486.
[3] WU S G,SHIH J Y .Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J].Molecular Cancer,2018,17(1):38.
[4] MITSUDOMI T,SUDA K,YATABE Y.Surgery for NSCLC in the era of personalized medicine [J].Nature Reviews Clinical Oncology,2013,10(4):235-244.
[5] NAN X,XIE C,YU X Y,et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer[J].Oncotarget,2017,8(43):75712-75726.
[6] LANGER C J.Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer：is afatinib better or simply newer? [J].J Clin Oncol,2013,31(27):3303-3306.
[7] WU S G,SHIH J Y.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J].Mol Cancer,2018,17(1):38.
[8] WU S G,LIU Y N,TSAI M F,et al.The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients [J].Oncotarget,2016,7(11).
[9]LU S,CAMIDGE R,YANG C,et al. P1.01-62 the third generation irreversible EGFR inhibitor HS-10296 in advanced non-small cell lung cancer patients[J].Journal of thoracic oncology:official publication of the International Association for the Study of Lung Cancer,2018,13(10)：S485.
[10] 邵宜,钟殿胜.EGFR突变丰度的检测及其临床意义[J].中国肺癌杂志,2017,20(008):578-583.
[11] KEEDY V L,TEMIN S,SOMERFIELD M R,et al.ASCO provisional clinical opinion：epidermal growth factor receptor(EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy [J].Clin Oncol,2011,29(15):2121-2127.
[12] WANG W,SONG Z,ZHANG Y.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance [J].Cancer Medicine,2017,6(1):154-162.
[13] ZHOU Q,ZHANG X C,CHEN Z H,et al.Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer[J].Clin Oncol,2011,29(24)：3316-3321.
[14] YANG X,ZHUO M,YE X,et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer[J].Oncotarget,2016,7(15)：20810-20824.
[15] IWAMA E,TAKAYAMA K,HARADA T,et al.Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR[J].Oncotarget,2015,6(24)：20466-20473.
[16] 邵岚,王文娴,石志永,等.EGFR T790M突变丰度对奥希替尼治疗晚期非小细胞肺癌疗效的影响[J].肿瘤学杂志,2020,26(7):7.

相似文献/References:

[1]林清华　吴联平　刘加夫　陈友轩　 齐春能　林玉琼　黄小红　郑　静.晚期非小细胞肺癌患者胸水液基细胞学蜡块中新抗体D5F3检测的临床价值[J].福建医药杂志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(01):3.
[2]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(01):6.
[3]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):23.
[4]李荣宾,黄延延,林贤宾,等.IGF1/RPI3K/Akt通路及其调控对非小细胞肺癌血管生成拟态形成影响的研究[J].福建医药杂志,2023,45(03):112.
[5]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(01):8.

更新日期/Last Update: 2024-02-15